How have EVG shares performed in 2024?

Evgen Pharma's stock was trading at GBX 1.60 at the start of the year. Since then, EVG stock has decreased by 51.6% and is now trading at GBX 0.78. View the best growth stocks for 2024 here .

How were Evgen Pharma's earnings last quarter?

Evgen Pharma plc (LON:EVG) issued its quarterly earnings results on Monday, June, 15th. The company reported ($2.10) EPS for the quarter, meeting the consensus estimate of ($2.10).

What other stocks do shareholders of Evgen Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evgen Pharma investors own include MOTIF BIO PLC/S (MTFB) , Capital & Counties Properties PLC (CAPC) , Obtala (OBT) , Tertiary Minerals (TYM) , Veltyco Group (VLTY) , Atalaya Mining (AYM) , AllianceBernstein Global High Income Fund (AWF) , Advent Convertible and Income Fund (AVK) , Ares Dynamic Credit Allocation Fund (ARDC) and UBS ETRACS Alerian MLP Index ETN (AMU) .

How do I buy shares of Evgen Pharma?

Shares of EVG stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. Compare Top Brokerages Here .

LON:EVG

Evgen Pharma (EVG) Share Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free EVG Stock Alerts

GBX 0.78

0.00 (0.00%)

(As of 04/18/2024 ET)

Compare

Today's Range: 0.78
▼
0.78
50-Day Range: 0.75
▼
1.20
52-Week Range: 0.70
▼
4.05

Volume: 110,000 shs
Average Volume: 1.73 million shs
Market Capitalization: £2.13 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Headlines

Get Evgen Pharma alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Evgen Pharma Stock (LON:EVG)

Evgen Pharma plc, a clinical stage drug development company, focuses on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. It develops its products using Sulforadex, a sulforaphane stabilization technology. The company's lead product is SFX-01, that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase Ib/IIa clinical trials for the treatment of glioblastoma, as well as in preclinical stage for the treatment of haematological malignancies and analogues. It also provides out-licensing of its technology services. Evgen Pharma plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.

EVG Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EVG Stock News Headlines

April 6, 2024 | insidertrades.com

Evgen Pharma plc (LON:EVG) Insider Acquires £10,000 in Stock

April 4, 2024 | lse.co.uk

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests

April 18, 2024 | TradeSmith (Ad)

A.I. Pioneer Issues Urgent Warning to Americans

With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.

March 20, 2024 | marketwatch.com

Evgen to Raise Up to $2.4 Mln; to Change Name After Acquiring Chronos Therapeutics

February 27, 2024 | lse.co.uk

Evgen Pharma finds evidence of SFX-01 activity in colon cancer models

February 14, 2024 | msn.com

Pharma middlemen face govt. scrutiny over generic drug shortages

January 26, 2024 | lse.co.uk

Evgen Pharma Share Chat

December 4, 2023 | finance.yahoo.com

Metastatic HR+/HER2− Breast Cancer Market is Expected to Showcase a Significant Growth at a CAGR of 9.3% by 2032, Predicts DelveInsight

April 18, 2024 | TradeSmith (Ad)

A.I. Pioneer Issues Urgent Warning to Americans

With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.

October 31, 2023 | finance.yahoo.com

Evgen Pharma "delighted" with cash position after promising first half

September 5, 2023 | lse.co.uk

Evgen Pharma hires interim CFO from Faron, chair to retire this month

September 5, 2023 | marketwatch.com

Evgen Pharma Chair Barry Clare Steps Down; Appoints New Interim Chair, Interim CFO

August 15, 2023 | marketwatch.com

Evgen Pharma Shares Rise on Positive SFX-01 Tablet Report

August 2, 2023 | marketwatch.com

Evgen Pharma Shares Fall on Ending of License Deal

June 19, 2023 | lse.co.uk

Evgen collaborator receives grant from KWF Dutch Cancer Society

June 7, 2023 | lse.co.uk

Evgen Pharma confident amid Stalicla deal; CFO Moulson to retire

March 22, 2023 | marketwatch.com

Evgen Pharma Results From SFX-01 Tablet Trial Meet Expectations

March 16, 2023 | marketwatch.com

Evgen Pharma Shares Rise on Drug Candidate Data

March 13, 2023 | msn.com

THG and musicMagpie move to reassure investors as Silicon Valley Bank's UK arm is sold to HSBC

November 16, 2022 | lse.co.uk

Evgen Pharma starts clinical trial of new SFX-01 tablet

October 13, 2022 | lse.co.uk

CORRECT: Coral Products buys Ecodeck; Evgen Pharma recruits

October 12, 2022 | lse.co.uk

TRADING UPDATES: Coral Products buys Ecodeck; Evgen Pharma recruits

October 11, 2022 | lse.co.uk

AIM WINNERS & LOSERS: Europa Oil, i3 Energy slide as well disappoints

October 11, 2022 | finance.yahoo.com

Companies Like Evgen Pharma (LON:EVG) Are In A Position To Invest In Growth

October 10, 2022 | proactiveinvestors.com.au

Market movers: Electricity generators fall on revenue cap reports

October 10, 2022 | msn.com

Shares in drug maker more then double after agreeing $160m deal

October 10, 2022 | benzinga.com

STALICLA to in-license SFX-01 from Evgen for neurodevelopment disorder indications

See More Headlines

Receive EVG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evgen Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 6/15/2020
Today: 4/18/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: LON
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: LON:EVG
CUSIP: N/A
CIK: N/A
Web: evgen.com
Phone: +44-151-7053532
Fax: N/A
Employees: 10
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): GBX (0.01)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: £-3,350,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -60.57%
Return on Assets: -45.52%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.39
Quick Ratio: 23.15

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: GBX 0.45 per share
Price / Cash Flow: 1.71
Book Value: GBX 1 per share
Price / Book: 0.78

Miscellaneous

Outstanding Shares: 274,890,000
Free Float: N/A
Market Cap: £2.13 million
Optionable: Not Optionable
Beta: 1.47

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. Huw Jones BSc (Age 65)
Ph.D., CEO & Executive Director
Comp: $304.73k
Mr. Toni Haenninen (Age 47)
CFO & Director
Dr. Helen Kuhlman
Chief Business Officer
Dr. Glen Clack FFPM
M.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders

Toni Hänninen
Bought 1,000,000 shares on 4/5/2024
Total: £1 M ($1.00/share)

EVG Stock Analysis - Frequently Asked Questions

How have EVG shares performed in 2024?: Evgen Pharma's stock was trading at GBX 1.60 at the start of the year. Since then, EVG stock has decreased by 51.6% and is now trading at GBX 0.78.
View the best growth stocks for 2024 here.
How were Evgen Pharma's earnings last quarter?: Evgen Pharma plc (LON:EVG) issued its quarterly earnings results on Monday, June, 15th. The company reported ($2.10) EPS for the quarter, meeting the consensus estimate of ($2.10).
What other stocks do shareholders of Evgen Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Evgen Pharma investors own include MOTIF BIO PLC/S (MTFB), Capital & Counties Properties PLC (CAPC), Obtala (OBT), Tertiary Minerals (TYM), Veltyco Group (VLTY), Atalaya Mining (AYM), AllianceBernstein Global High Income Fund (AWF), Advent Convertible and Income Fund (AVK), Ares Dynamic Credit Allocation Fund (ARDC) and UBS ETRACS Alerian MLP Index ETN (AMU).
How do I buy shares of Evgen Pharma?: Shares of EVG stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:EVG) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial